An 8-Day Losing Streak Has Stryker Stock Down 18%
A persistent slide in the medical equipment maker’s stock prompts a closer look at its underlying business metrics.
Stryker (SYK) stock has fallen 18% over its last eight trading sessions, a decline that has erased about $23 billion from its market value.
That move leaves the company’s market value at about $104 billion and has pushed the stock to its 52-week low of $270.01.
SYK Versus The S&P 500, Streak And Beyond
Here is how SYK stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | SYK | S&P 500 |
|---|---|---|
| 1D | -2.0% | -0.6% |
| 8D (Current Streak) | -18.3% | -1.6% |
| 1M (21D) | -22.4% | -1.8% |
| 3M (63D) | -12.3% | 4.5% |
| YTD 2026 | -22.8% | 10.9% |
| 2025 | -1.5% | 16.4% |
| 2024 | 21.3% | 23.3% |
| 2023 | 23.8% | 24.2% |
The stock’s slide is its own, while its fundamentals are a mixed bag.
This streak is not a reflection of the broader market’s recent performance. Over the same 8 trading days the S&P 500 returned -1.6%, so the streak is mostly this stock’s own story. For context, 6 other S&P 500 stocks are currently on losing streaks of 8 days or more.
There is no single headline or company catalyst explaining the stock’s eight-day slide. They do show a business that is solid but not exceptional. Revenue over the last twelve months grew 8.5%, just ahead of the S&P 500 median revenue growth of 8.3%. Its operating margin of 21.7% also tops the S&P 500 median of 18.6%. However, SYK trades at a price-to-earnings multiple of 27.8, versus an S&P 500 median of 22.6 and a median of 25.0 among S&P 500 Health Care stocks.
A streak is a signal, not a command.
A long streak signals that a stock has captured attention, but it doesn’t provide an instruction. The disciplined move is to check the business against the price. The recent slide brings its one-month return to -22.4% and pushes its twelve-month decline to -30.6%.
This kind of focused selling pressure creates an opportunity to re-evaluate whether the current price reflects the company’s underlying financial health, including its 3-year average annual revenue growth of 9.9% and its free cash flow yield of 4.5%.
A slide like this always raises the question of which pullbacks present compelling risk-reward profiles. Our Buy the Dip screen filters for beaten-down names where balance-sheet and growth fundamentals remain intact.
And for anyone who would rather back the theme than one company’s story, a healthcare ETF like XLV holds the sector rather than this one name. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.